Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events

Bibliography

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78
   PubMed Web of Science ®Google Scholar
• Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1993;94:174-81
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53
   PubMed Web of Science ®Google Scholar
• Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn’s disease. Lancet 1993;342:173-4
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029-35
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Janssen, personal communication
   Google Scholar
• Adcock IM. Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther 2000;13:115-26
   PubMed Web of Science ®Google Scholar
• Ardite E, Panés J, Miranda M, et al. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br J Pharmacol 1998;124:431-3
   PubMed Web of Science ®Google Scholar
• Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-18
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:590-9
   PubMed Web of Science ®Google Scholar
• Yang YX, Lichtenstein GR. Corticosteroids in Crohn’s disease. Am J Gastroenterol 2002;97:803-23
   PubMed Web of Science ®Google Scholar
• Raj SL, Hawthorne AB. Optimising use of thiopurines in inflammatory bowel disease. Frontline Gastroenterol 2010;1:44-51
   Google Scholar
• Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2014;109:163-9
   PubMed Web of Science ®Google Scholar
• McKendry RJ. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997;23:939-54
   PubMed Web of Science ®Google Scholar
• Panés J, López-Sanromán A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 2013;145:766-74
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology 2013;145:758-6
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383-95
   PubMed Web of Science ®Google Scholar
• Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:630-42
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995;332:292-7
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000;342:1627-32
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 2014;146:681-8
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005;353:362-8
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660-7
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012;107:1409-22
   PubMed Web of Science ®Google Scholar
• Lichtenstein G, Cohen RD, Feagan BG, et al. Risk factors for serious infections in patients receiving infliximab and other Crohn’s disease therapies: TREAT™ Registry Data. Gastroenterology 2010;138:S-475
   Google Scholar
• Toruner M, Loftus EVJr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;CD008794
   PubMedGoogle Scholar
• Fellermann K. Adverse events of tumor necrosis factor inhibitors. Dig Dis 2013;31:374-8
   PubMed Web of Science ®Google Scholar
• de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37
   PubMed Web of Science ®Google Scholar
• Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol 2013;230:241-8
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and antimetabolite-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051-63
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ Registry. Am J Gastroenterol 2014;109:212-23
   PubMed Web of Science ®Google Scholar
• Arora A, Attwood J. Common skin cancers and their precursors. Surg Clin North Am 2009;89:703-12
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-85
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L1, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8
   PubMed Web of Science ®Google Scholar
• Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010;32:119-30
   PubMed Web of Science ®Google Scholar
• Carlesimo M, La Pietra M, Arcese A, et al. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists. Int J Dermatol 2012;51:1234-6
   PubMed Web of Science ®Google Scholar
• Khan I, Rahman L, McKenna DB. Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol 2009;34:524-6
   PubMed Web of Science ®Google Scholar
• Jones JL, Loftus EVJr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007;13:1299-307
   PubMed Web of Science ®Google Scholar
• Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-22
   PubMed Web of Science ®Google Scholar
• Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62
   PubMed Web of Science ®Google Scholar
• Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015-19
   PubMed Web of Science ®Google Scholar
• Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004;19:287-93
   PubMed Web of Science ®Google Scholar
• Karlen P, Lofberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999;94:1047-52
   PubMed Web of Science ®Google Scholar
• Loftus EVJr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308-12
   PubMed Web of Science ®Google Scholar
• Palli D, Trallori G, Bagnoli S, et al. Hodgkin’s disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000;119:647-53
   PubMed Web of Science ®Google Scholar
• Persson PG, Karlen P, Bernell O, et al. Crohn’s disease and cancer: a population-based cohort study. Gastroenterology 1994;107:1675-9
   PubMed Web of Science ®Google Scholar
• Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088-95
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and antimetabolite therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81
   PubMed Web of Science ®Google Scholar
• Visnyei K, Grossbard ML, Shapira I. Hepatosplenic γδ T-cell lymphoma: an overview. Clin Lymphoma Myeloma Leuk 2013;13:360-9
   PubMed Web of Science ®Google Scholar
• Morice WG, Macon WR, Dogan A, et al. NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis. Leukemia 2006;883-6
   PubMed Web of Science ®Google Scholar
• Safety review update on reports of hepatosplenic T-cell lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and/or mercaptopurine. FDA drug safety communication, Washington, DC; 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm250913.htm [Last accessed 11 November 2014]
   Google Scholar
• Infliximab: hepatosplenic T cell lymphoma. WHO Drug Information 2006;20:181
   Google Scholar
• Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261-9
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7
   PubMed Web of Science ®Google Scholar
• Wetter DA, Davis MDP. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009;84:979-84
   PubMed Web of Science ®Google Scholar
• De Bant M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French survey. Arthritis Res Ther 2005;7:R545-51
   PubMed Web of Science ®Google Scholar
• Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology 2009;48:716-20
   PubMed Web of Science ®Google Scholar
• Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut 2009;58:1033-9
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51
   PubMed Web of Science ®Google Scholar
• Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37:381-7
   PubMed Web of Science ®Google Scholar
• Rubin RL. Drug-induced lupus. Toxicology 2005;209:135-47
   PubMed Web of Science ®Google Scholar
• Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011;50:619-25
   PubMed Web of Science ®Google Scholar
• Wetter DA, Davis MDP. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009;84:979-84
   PubMed Web of Science ®Google Scholar
• Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor a treatment. J Neurol 2010;257:1421-31
   PubMed Web of Science ®Google Scholar
• Mahil SK, Andrews TC, Brierley C, et al. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. J Dermatolog Treat 2013;24:38-49
   PubMed Web of Science ®Google Scholar
• Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912
   PubMed Web of Science ®Google Scholar
• Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34
   PubMed Web of Science ®Google Scholar
• Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol 2006;12:5606-10
   PubMed Web of Science ®Google Scholar
• Cingoz O. Ustekinumab. MAbs 2009;1:216-21
   PubMed Web of Science ®Google Scholar
• Kamdar K, Nguyen V, DePaolo RW. Toll-like receptor signaling and regulation of intestinal immunity. Virulence 2013;4:207-12
   PubMed Web of Science ®Google Scholar
• Duvallet E, Semerano L, Assier E, et al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med 2011;43:503-11
   PubMed Web of Science ®Google Scholar
• Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol 2013;168:1325-34
   PubMed Web of Science ®Google Scholar
• Famenini S, Wu JJ. Infliximab-induced psoriasis in treatment of Crohn’s disease-associated ankylosing spondylitis: case report and review of 142 cases. J Drugs Dermatol 2013;12:939-43
   PubMed Web of Science ®Google Scholar
• Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010;8:1048-55
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8
   PubMed Web of Science ®Google Scholar
• Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76
   PubMed Web of Science ®Google Scholar
• Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014;13:15-19
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008;135:1130-41
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012;367:1519-28
   PubMed Web of Science ®Google Scholar
• Puig L, Morales-Múnera CE, López-Ferrer A, et al. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 2012;225:14-17
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut 2014;10.1136/gutjnl-2014-307883
   PubMedGoogle Scholar
• Afif W, Loftus EVJr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014;16:378
   PubMedGoogle Scholar
• Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Gils A, Ballet V, et al. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study. United European Gastroenterol J 2013;1:A1
   Google Scholar
• Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut 2011;60:1754-63
   PubMed Web of Science ®Google Scholar
• Levesque BG, Sandborn WJ, Ruel J, et al. Converging goals of treatment for inflammatory bowel disease, from clinical trials and practice. Gastroenterology 2015;148(1):37-51; e1
   PubMed Web of Science ®Google Scholar